Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials

Amit Khatri; Sandra Goss; Ping Jiang; Heikki Mansikka; Ahmed A. Othman

doi:10.1007/s40262-017-0580-y

Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials

Clinical Pharmacokinetics ◽

10.1007/s40262-017-0580-y ◽

2017 ◽

Vol 57 (5) ◽

pp. 613-623 ◽

Cited By ~ 10

Author(s):

Amit Khatri ◽

Sandra Goss ◽

Ping Jiang ◽

Heikki Mansikka ◽

Ahmed A. Othman

Keyword(s):

Rheumatoid Arthritis ◽

Phase I ◽

Healthy Subjects ◽

Variable Domain ◽

Phase I Trials ◽

Dual Variable ◽

Three Phase ◽

Tnf Α

Download Full-text

Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials

The Journal of Clinical Pharmacology ◽

10.1002/jcph.1068 ◽

2018 ◽

Vol 58 (6) ◽

pp. 803-813 ◽

Cited By ~ 8

Author(s):

Amit Khatri ◽

Ahmed A. Othman

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trials ◽

Healthy Volunteers ◽

Population Pharmacokinetics ◽

Phase 1 ◽

Variable Domain ◽

Dual Variable ◽

Domain Antibody ◽

Tnf Α

Download Full-text

176 POSTER Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72108-6 ◽

2008 ◽

Vol 6 (12) ◽

pp. 56 ◽

Cited By ~ 1

Author(s):

P. Schöffski ◽

V. Grünwald ◽

G. Giaccone ◽

R. Salazar ◽

M. Majem ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trials ◽

Three Phase ◽

Marine Compound

Download Full-text

Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1α and IL-1β in Healthy Subjects and Patients With Osteoarthritis of the Knee

The Journal of Clinical Pharmacology ◽

10.1002/jcph.764 ◽

2016 ◽

Vol 56 (12) ◽

pp. 1582-1590 ◽

Cited By ~ 15

Author(s):

Matthew P. Kosloski ◽

Sandra Goss ◽

Susanne X. Wang ◽

Jia Liu ◽

Ralf Loebbert ◽

...

Keyword(s):

Healthy Subjects ◽

Variable Domain ◽

Osteoarthritis Of The Knee ◽

Dual Variable

Download Full-text

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

Clinical Pharmacokinetics ◽

10.1007/s40262-017-0605-6 ◽

2017 ◽

Vol 57 (8) ◽

pp. 977-988 ◽

Cited By ~ 35

Author(s):

Ben Klünder ◽

Mohamed-Eslam F. Mohamed ◽

Ahmed A. Othman

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trials ◽

Phase I ◽

Population Pharmacokinetics ◽

Healthy Subjects ◽

Phase I And Ii

Download Full-text

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

Clinical Pharmacokinetics ◽

10.1007/s40262-019-00739-3 ◽

2019 ◽

Vol 58 (8) ◽

pp. 1045-1058 ◽

Cited By ~ 20

Author(s):

Ben Klünder ◽

Rajendar K. Mittapalli ◽

Mohamed-Eslam F. Mohamed ◽

Anna Friedel ◽

Peter Noertersheuser ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trials ◽

Phase I ◽

Population Pharmacokinetics ◽

Healthy Subjects ◽

Extended Release ◽

Immediate Release ◽

Extended Release Formulations

Download Full-text

FRI0176 ABT-122, A Novel Dual Variable Domain (DVD)-IG™, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1544 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 487.2-487 ◽

Cited By ~ 2

Author(s):

M. Ruzek ◽

D. Conlon ◽

H. Mansikka ◽

R.J. Padley ◽

C. Cuff

Keyword(s):

Peripheral Blood Mononuclear Cell ◽

Mononuclear Cell ◽

Peripheral Blood ◽

Healthy Subjects ◽

Variable Domain ◽

Dual Variable ◽

Peripheral Blood Mononuclear ◽

Cell Production ◽

Gm Csf

Download Full-text

FRI0188 Safety, Tolerability, and Pharmacodynamics of ABT-122, A Dual TNF- and IL-17–Targeted Dual Variable Domain (DVD)-IG™ in Patients with Rheumatoid Arthritis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3676 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 498.1-498 ◽

Cited By ~ 1

Author(s):

R.M. Fleischmann ◽

F. Wagner ◽

A.J. Kivitz ◽

H.T. Mansikka ◽

N. Khan ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Variable Domain ◽

Dual Variable

Download Full-text

Faculty Opinions recommendation of Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.731259662.793550509 ◽

2018 ◽

Author(s):

Paul Emery ◽

Leticia Garcia-Montoya

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Variable Domain ◽

Interleukin 17 ◽

Dual Variable ◽

Necrosis Factor

Download Full-text

Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis

Arthritis & Rheumatology ◽

10.1002/art.40319 ◽

2017 ◽

Vol 69 (12) ◽

pp. 2283-2291 ◽

Cited By ~ 20

Author(s):

Roy M. Fleischmann ◽

Frank Wagner ◽

Alan J. Kivitz ◽

Heikki T. Mansikka ◽

Nasser Khan ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Variable Domain ◽

Interleukin 17 ◽

Dual Variable ◽

Necrosis Factor

Download Full-text

Corrigendum to “Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and QT Interval for Healthy Subjects Who Received Placebo in Phase I Trials”

Clinical and Translational Science ◽

10.1111/cts.12773 ◽

2020 ◽

Vol 13 (3) ◽

pp. 638-638

Keyword(s):

Blood Pressure ◽

Heart Rate ◽

Circadian Rhythm ◽

Phase I ◽

Qt Interval ◽

Healthy Subjects ◽

Phase I Trials

Download Full-text